Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus | Zendy

Fabio BonillaAbadía | Zendy; Nicolás Coronel | Zendy; Gabriel J. Tobón | Zendy; Á. García | Zendy; Evelyn Muñoz-Buitrón | Zendy; Andrés Castro | Zendy; Mercedes Andrade Bejarano | Zendy; Carlos A. Cañas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rituximab for Remission Induction and Maintenance in Refractory Systemic Lupus Erythematosus

Author(s) -

Fabio BonillaAbadía,

Nicolás Coronel,

Gabriel J. Tobón,

Á. García,

Evelyn Muñoz-Buitrón,

Andrés Castro,

Mercedes Andrade Bejarano,

Carlos A. Cañas

Publication year - 2014

Publication title -

autoimmune diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.681

H-Index - 32

eISSN - 2090-0422

pISSN - 2090-0430

DOI - 10.1155/2014/731806

Subject(s) - medicine , rituximab , refractory (planetary science) , maintenance therapy , retrospective cohort study , disease , drug , cumulative dose , systemic lupus erythematosus , autoimmune disease , immunology , gastroenterology , chemotherapy , pharmacology , lymphoma , physics , astrobiology

Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research